Oligofructose-enriched inulin improves some inflammatory markers and metabolic endotoxemia in women with type 2 diabetes mellitus: A randomized controlled clinical trial

Nutrition

Volumn 30, Issue 4, 2014, Pages 418-423

  Dehghan, Parvin ^a   Pourghassem Gargari, Bahram ^b   Asghari Jafar abadi, Mohammad ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Interleukin; Lipopolysaccharide; Prebiotics; Tumor necrosis factor

Indexed keywords

C REACTIVE PROTEIN; GAMMA INTERFERON; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INTERLEUKIN 10; INTERLEUKIN 6; INULIN; LIPOPOLYSACCHARIDE; MALTODEXTRIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIETARY FIBER; DIETARY INTAKE; ENDOTOXEMIA; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

INTERLEUKIN; LIPOPOLYSACCHARIDE; PREBIOTICS; TUMOR NECROSIS FACTOR-Α;

ADULT; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY MASS INDEX; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; ENDOTOXEMIA; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INFLAMMATION; INTERFERON-GAMMA; INTERLEUKIN-6; INULIN; LIPOPOLYSACCHARIDES; MIDDLE AGED; OLIGOSACCHARIDES; PREBIOTICS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84895460130     PISSN: 08999007     EISSN: 18731244     Source Type: Journal    
DOI: 10.1016/j.nut.2013.09.005     Document Type: Article

References (42)

1. Fernández-Real J.M., Pickup J.C. Innate immunity, insulin resistance and type 2 diabetes. Trends Endocrinol Metab 2008, 19:10-16.
2. Andreasen A.S., Pedersen-Skovsgaard T., Berg R.M., Svendsen K.D., Feldt-Rasmussen B., Pedersen B.K., et al. Type 2 diabetes mellitus is associated with impaired cytokine response and adhesion molecule expression in human endotoxemia. Intensive Care Med 2010, 36:1548-1555.
3. Goldberg R.B. Cytokine and cytokine-like inflammation markers, endothelial dysfunction and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab 2009, 94:3171-3182.
4. Cani P.D., Bibiloni R., Knauf C., Waget A., Neyrinck A.M., Delzenne N.M., et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008, 57:1470-1481.
5. Suganami T., Mieda T., Itoh M., Shimoda Y., Kamei Y., Ogawa Y. Attenuation of obesity-induced adipose tissue inflammation in C3H/HeJ mice carrying a Toll-like receptor 4 mutation. Biochem Biophys Res Commun 2007, 354:45-49.
6. Knaapen M., Kootte R.S., Zoetendal E.G., de Vos W.M., Dallinga-Thie G.M., Levi M., et al. Obesity, non-alcoholic fatty liver disease, and atherothrombosis: a role for the intestinal microbiota?. Clin Microbiol Infect 2013, 19:331-337.
7. Creely S.J., McTernan P.G., Kusminski C.M., Fisher M., Da Silva N.F., Khanolkar M., et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab 2007, 292:E740-E747.
8. Caesar R., Fåk F., Bäckhed F. Effects of gut microbiota on obesity and atherosclerosis via modulation of inflammation and lipid metabolism. J Intern Med 2010, 268:320-328.
9. Burcelin R., Serino M., Chabo C., Blasco-Baque V., Amar J. Gut microbiota and diabetes: from pathogenesis to therapeutic perspective. Acta Diabetol 2011, 48:257-273.
10. Roberfroid M.B. Inulin-type fructans: functional food ingredients. J Nutr 2007, 137:2493S-2502S.
11. Langlands S.J., Hopkins M.J., Coleman N., Cummings J.H. Prebiotic carbohydrates modify the mucosa associated microflora of the human large bowel. Gut 2004, 53:1610-1616.
12. Poulsen M., Mølck A.M., Jacobsen B.L. Different effects of short- and long-chained fructans on large intestinal physiology and carcinogen-induced aberrant crypt foci in rats. Nutr Cancer 2002, 42:194-205.
13. Kolida S., Gibson G.R. Prebiotic capacity of inulin-type fructans. J Nutr 2007, 137(11 Suppl):2503S-2506S.
14. Cani P.D., Possemiers S., Van de Wiele T., Guiot Y., Everard A., Rottier O., et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009, 58:1091-1103.
15. Yasuda K., Dawson H.D., Wasmuth E.V., Roneker C.A., Chen C., Urban J.F., et al. Supplemental dietary inulin influences expression of iron and inflammation related genes in young pigs. J Nutr 2009, 139:2018-2023.
16. Cani P.D., Neyrinck A.M., Fava F., Knauf C., Burcelin R.G., Tuohy K.M., et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 2007, 50:2374-2383.
17. Malaguarnera M., Vacante M., Antic T., Giordano M., Chisari G., Acquaviva R., et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci 2012, 57:545-553.
18. Dewulf E.M., Cani P.D., Claus S.P., Fuentes S., Puylaert P.G., Neyrinck A.M., et al. Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. Gut 2013, 62:1112-1121.
19. Lecerf J.M., Dépeint F., Clerc E., Dugenet Y., Niamba C.N., Rhazi L., et al. Xylo-oligosaccharide (XOS) in combination with inulin modulates both the intestinal environment and immune status in healthy subjects, while XOS alone only shows prebiotic properties. Br J Nutr 2012, 108:1847-1858.
20. Nilsson A.C., Ostman E.M., Holst J.J., Björck I.M. Including indigestible carbohydrates in the evening meal of healthy subjects improves glucose tolerance, lowers inflammatory markers, and increases satiety after a subsequent standardized breakfast. J Nutr 2008, 138:732-739.
21. Zenhom M., Hyder A., de Vrese M., Heller K.J., Roeder T., Schrezenmeir J. Prebiotic oligosaccharides reduce proinflammatory cytokines in intestinal Caco-2 cells via activation of PPARγ and peptidoglycan recognition protein 3. J Nutr 2011, 141:971-977.
22. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004, 27:S5-10. American Diabetes Association.
23. Pocock S.J. Clinical trials - a practical approach 1990, 128. John Wiley & Sons, Chichester, NY.
24. Parnell J.A., Reimer R.A. Weight loss during oligofructose supplementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adults. Am J Clin Nutr 2009, 89:1751-1759.
25. Pourghassem Gargari B., Dehghan P., Aliasgharzadeh A., Asghari Jafar-Abadi M. Effects of high performance inulin supplementation on glycemic control and antioxidant status in women with type 2 diabetes. Diabetes Metab J 2013, 37:140-148.
26. Cani P.D., Delzenne N.M. The role of the gut microbiota in energy metabolism and metabolic disease. Curr Pharm Des 2009, 15:1546-1558.
27. Yamashita K., Kawai K., Itakura M. Effects of fructooligosaccharides on blood glucose and serum lipids in diabetic subjects. Nutr Res 1984, 4:961-966.
28. Alles M.S., de Roos N.M., Bakx J.C., van de Lisdonk E., Zock P.L., Hautvast G.A. Consumption of fructooligosaccharides does not favorably affect blood glucose and serum lipid concentrations in patients with type 2 diabetes. Am J Clin Nutr 1999, 69:64-69.
29. Bonsu N.K.A., Johnson C.S., Mcleod K.M. Can dietary fructans lower serum glucose?. J Diabetes 2011, 3:58-66.
30. Canadian Diabetes Association. The benefits of eating fiber. Available at:. Accessed April 10, 2013. http://www.diabetes.ca/diabetes-and-you/nutrition/fibre/.
31. Cherbut C. Motor effects of short-chain fatty acids and lactate in the gastrointestinal tract. Proc Nutr Soc 2003, 62:95-99.
32. Cani P.D., Knauf C., Iglesias M.A., Drucker D.J., Delzenne N.M., Burcelin R. Improvement of glucose tolerance and hepatic insulin sensitivity by oligofructose requires a functional glucagon-like peptide 1 receptor. Diabetes 2006, 55:1484-1490.
33. Pouillart P.R., Dépeint F., Abdelnour A., Deremaux L., Vincent O., Mazière J.C., et al. Nutriose, a prebiotic low-digestible carbohydrate, stimulates gut mucosal immunity and prevents TNBS-induced colitis in piglets. Inflamm Bowel Dis 2010, 16:783-794.
34. Anderson A.D., McNaught C.E., Jain P.K., MacFie J. Randomised clinical trial of synbiotic therapy in elective surgical patients. Gut 2004, 53:241-245.
35. Jain P.K., McNaught C.E., Anderson A.D., MacFie J., Mitchell C.J. Influence of symbiotic containing Lactobacillus acidophilus La5, Bifidobacterium lactis Bb 12, Streptococcus thermophilus, Lactobacillus bulgaricus and oligofructose on gut barrier function and sepsis in critically ill patients: a randomized controlled trial. Clin Nutr 2004, 23:467-475.
36. King G.L., Loeken M.R. Hyperglycemia-induced oxidative stress in diabetic complications. Histochem Cell Biol 2004, 122:333-338.
37. Everard A., Belzer C., Geurts L., Ouwerkerk J.P., Druart C., Bindels L.B., et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci USA 2013, 110:9066-9071.
38. Place R.F., Noonan E.J., Giardina C. HDAC inhibition prevents NF-kappa B activation by suppressing proteasome activity: down-regulation of proteasome subunit expression stabilizes I kappa B alpha. Biochem Pharmacol 2005, 70:394-406.
39. Fusunyan R.D., Quinn J.J., Fujimoto M., MacDermott R.P., Sanderson I.R. Butyrate switches the pattern of chemokine secretion by intestinal epithelial cells through histone acetylation. Mol Med 1999, 5:631-640.
40. Schwab M., Reynders V., Loitsch S., Steinhilber D., Stein J., Schröder O. Involvement of different nuclear hormone receptors in butyrate-mediated inhibition of inducible NF kappa B signaling. Mol Immunol 2007, 44:3625-3632.
41. Cornell R.P. Mechanisms of acute hyperinsulinemia after Kupffer cell phagocytosis. Am J Physiol 1980, 238:E276-E283.
42. Sharman M.J., Volek J.S. Weight loss leads to reductions in inflammatory biomarkers after a very-low-carbohydrate diet and a low-fat diet in overweight men. Clin Sci (Lond) 2004, 107:365-369.